A Randomized Controlled Trial with a Medical Device Containing Sodium Hyaluronate and Nicotinic Acid to Increase the Efficacy of Ultraviolet Phototherapy in Psoriasis.
Optical cleaning
Phototherapy
Psoriasis
Ultraviolet B
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
01
04
2020
pubmed:
10
5
2020
medline:
10
5
2020
entrez:
10
5
2020
Statut:
ppublish
Résumé
The dry and scaly skin of psoriatic patients decreases the efficacy of ultraviolet B (UVB) phototherapy. Different agents are used to facilitate the transmission of light, but most of these preparations are cosmetically unfavorable. We have tested a novel preparation containing sodium hyaluronate and nicotinic acid (UV Fotogel®; Pernix Ltd.) with the double aim to improve the efficacy of UVB phototherapy and assess the cosmetic acceptability of the preparation. Ninety patients with plaque psoriasis were enrolled in the study, of whom 44 received narrow-band UVB (NB-UVB) phototherapy. Prior to phototherapy, one side of the patient's body was treated with UV Fotogel while the other side served as a control. The other 46 patients used the preparation at their homes before regular sunbathing. The Local Psoriasis Severity Index (L-PSI), cosmetic acceptability and tolerability were recorded. The median values with the 25th and 75th percentiles (25p and 75p, respectively) were determined for the UV Fotogel-treated and control sites and then compared. The sides of the body to which UV Fotogel was applied prior to NB-UVB phototherapy had a significantly lower median L-PSI score than the non-treated control sides at the end of the treatment (1.0 [25p-75p: 0.0-2.0] vs. 2.0 [1.0-3.0], respectively). The application of UV Fotogel prior to sunbathing also led to a significant decrease in L-PSI score. There was a significant reduction in the median L-PSI score of patients at the final visit compared to baseline (2.5 [25p-75p: 1.5-3.5] vs. 6.0 [6.0-7.0], respectively). Use of the preparation was not accompanied by considerable adverse effects, and the patients found it cosmetically acceptable. Application of UV Fotogel prior to sunbathing was well tolerated by the patients, and the cosmetic acceptability was also good. UV Fotogel is potentially a useful device for enhancement of the efficacy of phototherapy in patients with psoriasis.
Identifiants
pubmed: 32385846
doi: 10.1007/s13555-020-00385-9
pii: 10.1007/s13555-020-00385-9
pmc: PMC7367973
doi:
Types de publication
Journal Article
Langues
eng
Pagination
651-662Subventions
Organisme : Europen Union and the Hungarian Government
ID : EFOP-3.6.2-16-2017-00009
Organisme : H2020 HCEMM
ID : 739593
Références
Parisi R, Symmons DP, Griffiths CE, Aschroft DM. Global epidemiology of psoriasis: a systemic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.
doi: 10.1038/jid.2012.339
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Phys. 2017;63:278–85.
Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol. 2000;39:41–4.
doi: 10.1046/j.1365-4362.2000.00878.x
Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57:957–62.
doi: 10.1016/j.jaad.2007.06.042
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.
doi: 10.1016/j.jaad.2008.12.032
Ashcroft DM, Po AL, Williams HC, Griffith CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320:963–7.
doi: 10.1136/bmj.320.7240.963
Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009;(2): CD005028.
Goldenberg G, Lanoue J, Dong J. New oral therapies for psoriasis: a comprehensive review. J Clin Aesthet Dermatol. 2016;9:25–8.
pubmed: 27672415
pmcid: 5022993
Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis. Arch Dermatol. 2012;148:1403–10.
doi: 10.1001/2013.jamadermatol.238
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.
doi: 10.1016/j.jaad.2008.02.039
Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2018;33:173–80.
doi: 10.1007/s10103-017-2360-1
Bónis B, Kemény L, Dobozy A, Bor Z, Szabó G, Ignácz F. 308 nm UVB excimer laser for psoriasis. Lancet. 1997;350:1522.
doi: 10.1016/S0140-6736(05)63945-1
Kemény L, Bónis B, Dobozy A, Bor Z, Szabó G, Ignácz F. 308-nm excimer laser therapy for psoriasis. Arch Dermatol. 2001;137:95–6.
pubmed: 11176674
Novák Z, Bónis B, Baltás E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B. 2002;67:32–8.
doi: 10.1016/S1011-1344(02)00280-4
Fetil E, Akarsu S, Ilknur T, Kusku E, Günes AT. Effects of some emollients on the transmission of ultraviolet. Photodermatol Photoimmunol Photomed. 2006;22:137–40.
doi: 10.1111/j.1600-0781.2006.00221.x
Otman SG, Edwards C, Pearse AD, Gambles BJ, Anstey AV. Modulation of ultraviolet (UV) transmission by emollients: relevance to narrowband UVB phototherapy and psoralen plus UVA photochemotherapy. Br J Dermatol. 2006;154:963–8.
doi: 10.1111/j.1365-2133.2006.07171.x
Jain VK, Bansal A, Aggarwal K, Jain K. Enhanced response of childhood psoriasis to narrow-band UV-B phototherapy with preirradiation use of mineral oil. Pediatr Dermatol. 2008;25:559–64.
doi: 10.1111/j.1525-1470.2008.00729.x
Seebode C, Lehmann J, Emmert S. Photocarcinogenesis and skin cancer prevention strategies. Anticancer Res. 2016;36:1371–8.
pubmed: 26977038
Benáková N. Phototherapy of psoriasis in the era of biologics: still in. Acta Dermatovenerol Croat. 2011;19:195–205.
pubmed: 21933648
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
doi: 10.1007/s00403-010-1080-1
Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712.
doi: 10.1136/bmj.e6712
Warnecke J, Wendt A. Antiinflammatory action of pale sulfonated shale oil in UVB erythema test. Inflamm Res. 1998;47:75–8.
doi: 10.1007/s000110050282
Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol. 1981;77:13–9.
doi: 10.1111/1523-1747.ep12479191
Gambichler T. Balneophototherapy for psoriasis saltwater baths and UV-B irradiation, revisited. Arch Dermatol. 2007;143:647–9.
doi: 10.1001/archderm.143.5.647
Tan SY, Buzney E, Mostaghimi A. Trends in phototherapy utilization among Medicare beneficiaries in the United States, 2000 to 2015. J Am Acad Dermatol. 2018;79:672–9.
doi: 10.1016/j.jaad.2018.03.018
Hudson-Peacock MJ, Diffey BL, Farr PM. Photoprotective action of emollients in ultraviolet therapy of psoriasis. Br J Dermatol. 1994;130:361–5.
doi: 10.1111/j.1365-2133.1994.tb02934.x
Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol. 1995;32:469–71.
doi: 10.1016/0190-9622(95)90071-3
Kemény L, Révész P, Csányi E. Composition for increasing of the effectiveness of UV-B therapy, process for the preparation thereof, and its use. Patent No.: US9839595. Alexandria: US Patent and Trademark Office.
Jang HJ, Shin CY, Kim KB. Safety evaluation of polyethylene glycol (PEG) compounds for cosmetic use. Toxicol Res. 2015;31:105–36.
doi: 10.5487/TR.2015.31.2.105
DRUGBANK. https://www.drugbank.ca/drugs/DB00627 .
Becker LC, Bergfeld WF, Belsito DV, et al. Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate. Int J Toxicol. 2009;28:5–67.
doi: 10.1177/1091581809337738
Nilsen LT, Soyland E, Krogstad AL. Estimated ultraviolet doses to psoriasis patients during climate therapy. Photodermatol Photoimmunol Photomed. 2009;25:202–8.
doi: 10.1111/j.1600-0781.2009.00443.x